Literature DB >> 8734458

Glomerular protein trafficking and progression of renal disease to terminal uremia.

A Benigni1, G Remuzzi.   

Abstract

Experimental and human studies indicate that altered glomerular permeability to proteins correlates with tubulointerstitial injury and subsequent glomerular scarring. Maneuvers that restore the selectivity of glomerular barrier to macromolecules limit renal injury in progressive nephropathies. The abnormal traffic of proteins through the glomerular capillary has an intrinsic renal toxicity linked to the process of over-reabsorption by proximal tubular cells. Excessive protein reabsorption induces functional alterations of tubular cells that overexpress inflammatory and vasoactive molecules, as indicated by in vitro or in vivo studies. Thus monocyte chemoattractant protein-1 and osteopontin may attract inflammatory cells into renal interstitium. Enhanced tubular endothelin-1 secretion, mainly toward the basolateral membrane of the cell, may stimulate interstitial macrophage infiltration and in addition may promote interstitial fibroblast proliferation and extracellular matrix synthesis, thus amplifying tubulointerstitial inflammation and injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8734458

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  3 in total

1.  Rapid development of glomerular injury and renal failure in mice lacking p53R2.

Authors:  David R Powell; Urvi Desai; Mary Jean Sparks; Gwenn Hansen; Jason Gay; Jeff Schrick; Zheng-Zheng Shi; John Hicks; Peter Vogel
Journal:  Pediatr Nephrol       Date:  2005-01-26       Impact factor: 3.714

2.  Mechanisms permitting nephrotic patients to achieve nitrogen equilibrium with a protein-restricted diet.

Authors:  B J Maroni; C Staffeld; V R Young; A Manatunga; K Tom
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

3.  Glomerular structural factors in progression of congenital nephrotic syndrome.

Authors:  Abhay N Vats; Brian Costello; Michael Mauer
Journal:  Pediatr Nephrol       Date:  2003-02-26       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.